CoChat

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer

Open access
Engstrom, Lars D., Aranda, Ruth, Waters, Laura, Moya, Krystal, Bowcut, Vickie, Vegar, Laura, Trinh, David, Hebbert, Allan, Smith, Christopher R., Kulyk, Svitlana, Lawson, J. David, He, Leo, Hover, Laura D., Fernandez-Banet, Julio, Hallin, Jill, Vanderpool, Darin, Briere, David M., Blaj, Alice, Marx, Matthew A., Rodon, Jordi, Offin, Michael, Arbour, Kathryn C., Johnson, Melissa L., Kwiatkowski, David J., Jänne, Pasi A., Haddox, Candace L., Papadopoulos, Kyriakos P., Henry, Jason T., Leventakos, Konstantinos, Christensen, James G., Shazer, Ronald, Olson, Peter · 2023 · Cancer Discovery
Cited by 217

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selecti­vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study. Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-23-0669

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 217

Metadata

Authors
Engstrom, L. D., Aranda, R., Waters, L., Moya, K., Bowcut, V., Vegar, L., Trinh, D., Hebbert, A., Smith, C. R., Kulyk, S., Lawson, J. D., He, L., Hover, L. D., Fernandez-Banet, J., Hallin, J., Vanderpool, D., Briere, D. M., Blaj, A., Marx, M. A., Rodon, J., Offin, M., Arbour, K. C., Johnson, M. L., Kwiatkowski, D. J., Jänne, P. A., Haddox, C. L., Papadopoulos, K. P., Henry, J. T., Leventakos, K., Christensen, J. G., Shazer, R., & Olson, P.
Venue
Cancer Discovery
Published
2023-08-08
Volume
13
Issue
11
Pages
2412-2431
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4385650986
Cited by
217
References
12
FWCI
16.21
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.